Introduction Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant penetration of Provigil (modafinil; Cephalon) and Xyrem (sodium oxybate; Jazz Pharma) and the associated increase in the awareness of the disorder.
Scope
Patient Patient potential including disease definition, etiology, prevalence, diagnosis, and treatment guideline review.
Review of the key unmet needs in the treatment of narcolepsy as identified by key opinion leaders interviewed for the report.
Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem.
Pipeline analysis with detailed profile for Nuvigil (armodafinil, Cephalon) and the theory behind potential label expansions beyond narcolepsy.
Report
Highlights Although generic versions of Cephalon's market leading treatment, Provigil (modafinil), are expected to launch in 2012, Datamonitor expects Cephalon to retain a significant position in the narcolepsy market by switching patients over from Provigil to its follow-up product, Nuvigil (armodafinil).
Despite Xyrem's (sodium oxybate) proven efficacy and its broader narcolepsy coverage than Provigil, Xyrem's sales continue to be limited because of its black box warning, restricted distribution and comparatively high price.
Targeting narcolepsy as a primary indication and then expanding Provigil's label coverage to other sleep disorders has proven commercially successful for Cephalon. Datamonitor believes companies could take this strategy a step further by using narcolepsy as an entry point to access the broader fatigue- or sleepiness-associated market.
Reasons
to Purchase
Quantify the narcolepsy market value in the US, 5EU and Japan and identify the drivers and resistors in this market.
Understand key opinion leader (KOL) views on topical issues in the current and future treatment of narcolepsy and associated disorders.
Appreciate the potential of off-label prescribing and indication expansions for treatments possessing narcolepsy as the primary indication.
Table
of Contents
Please click on the link below to view further information on this product (a new window
will open):
If you require further
information on this product or would like to purchase by invoice call our customer service
number:
(+1) 800-759-0261 or Email
us.
If you require assistance please Email
us or call +1-800-759-0261.
